Literature DB >> 1939181

Mechanism of the potentiating effect of ribavirin on the activity of 2',3'-dideoxyinosine against human immunodeficiency virus.

J Balzarini1, C K Lee, P Herdewijn, E De Clercq.   

Abstract

Ribavirin enhances the anti-human immunodeficiency virus activity of 2',3'-dideoxyinosine (ddIno) in MT-4, CEM and peripheral blood lymphocyte cells. Ribavirin causes an increase in the levels of IMP, the presumed phosphate donor for the conversion of ddIno to ddIMP by 5'-nucleotidase. Consequently, ribavirin stimulates the conversion of ddIno to its antivirally active metabolite ddATP. Ribavirin also causes a marked depletion of the guanine nucleotide pools. The increase in IMP pool levels may result from (i) a direct inhibitory effect of ribavirin 5'-monophosphate on IMP dehydrogenase (which converts IMP to XMP) and (ii) an indirect inhibition of adenylosuccinate synthetase by the decreased GTP and dGTP pools (since GTP is an obligatory cofactor in the conversion of IMP to succinyl AMP). GTP depletion plays a key role in the accumulation of IMP and the resultant higher rate of ddIno phosphorylation to ddIMP and eventually ddATP. Our findings are in agreement with the observations that guanosine and 2'-deoxyguanosine, but not 2'-deoxyadenosine, reverse (i) the stimulatory effect of ribavirin on the anti-human immunodeficiency virus activity of ddIno and (ii) the accumulation of endogenous IMP pools as well as accumulation of [3H]IMP from exogenous [3H]hypoxanthine in ribavirin-treated cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1939181

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  Plasma and intracellular ribavirin concentrations are not significantly altered by abacavir in hepatitis C virus-infected patients.

Authors:  Edward J Fuchs; Jennifer J Kiser; Craig W Hendrix; Mark Sulkowski; Christine Radebaugh; Lane Bushman; Michelle L Ray; Adriana Andrade
Journal:  J Antimicrob Chemother       Date:  2016-02-10       Impact factor: 5.790

2.  Exploiting the anti-HIV-1 activity of acyclovir: suppression of primary and drug-resistant HIV isolates and potentiation of the activity by ribavirin.

Authors:  Christophe Vanpouille; Andrea Lisco; Andrea Introini; Jean-Charles Grivel; Arshi Munawwar; Melanie Merbah; Raymond F Schinazi; Marco Derudas; Christopher McGuigan; Jan Balzarini; Leonid Margolis
Journal:  Antimicrob Agents Chemother       Date:  2012-02-06       Impact factor: 5.191

Review 3.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

4.  Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines.

Authors:  Harshad Devarbhavi; Guruprasad Aithal; Sombat Treeprasertsuk; Hajime Takikawa; Yimin Mao; Saggere M Shasthry; Saeed Hamid; Soek Siam Tan; Cyriac Abby Philips; Jacob George; Wasim Jafri; Shiv K Sarin
Journal:  Hepatol Int       Date:  2021-02-27       Impact factor: 6.047

5.  Synthesis of carbocyclic nucleoside analogs with five-membered heterocyclic nucleobases.

Authors:  Jong Hyun Cho; Steven J Coats; Raymond F Schinazi
Journal:  Tetrahedron Lett       Date:  2015-06-03       Impact factor: 2.415

6.  In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus.

Authors:  T Shaw; P Amor; G Civitico; M Boyd; S Locarnini
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

Review 7.  Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action.

Authors:  Caroline Bazzoli; Vincent Jullien; Clotilde Le Tiec; Elisabeth Rey; France Mentré; Anne-Marie Taburet
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

8.  Assay method for monitoring the inhibitory effects of antimetabolites on the activity of inosinate dehydrogenase in intact human CEM lymphocytes.

Authors:  J Balzarini; E De Clercq
Journal:  Biochem J       Date:  1992-11-01       Impact factor: 3.857

9.  The antiherpesvirus activity of H2G [(R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine] is markedly enhanced by the novel immunosuppressive agent mycophenolate mofetil.

Authors:  J Neyts; G Andrei; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

Review 10.  Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection.

Authors:  D Faulds; R N Brogden
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.